pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
737
stories
Sep 30, 26
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
Sep 30, 26
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
stat
Sep 30, 26
STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader
stat
Sep 30, 26
STAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and more
stat
Sep 30, 26
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
Sep 30, 26
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
Sep 30, 26
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
fiercebiotech
Sep 30, 26
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
Sep 29, 26
#EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's
endpoints
Sep 29, 26
#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold
endpoints
Sep 29, 26
STAT+: Lawmakers urge Trump to rethink new rule that could restrict imported meds from Canada and overseas
stat
Sep 29, 26
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
stat
Sep 29, 26
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
Sep 29, 26
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
Sep 29, 26
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
Sep 29, 26
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
stat
Sep 29, 26
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
Sep 29, 26
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
stat
Sep 29, 26
Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug
endpoints
Sep 29, 26
Opinion: Child health is the national security crisis we keep ignoring
stat
Sep 29, 26
STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
stat
Sep 29, 26
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
Sep 29, 26
Recon: FDA approves Egetis’ Emcitate for rare genetic disease; Novo buys rights to Chinese weight-loss pill in $2.6B deal
raps
Sep 28, 26
Roche cans muscle-preserving obesity drug, hands it back to Chugai
endpoints
Sep 28, 26
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
Sep 28, 26
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
Sep 28, 26
Trump uses ‘contested’ power to cut more funding to HHS
stat
Sep 28, 26
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
Sep 28, 26
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
← prev
page 8 of 25
next →